Signos Scores Fda Clearance For First Otc Glucose Monitor For Weight Loss

As GLP-1 drugs reshape the weight-loss market, Signos offers a glucose monitoring system as a tool that can work alongside GLP-1 medications or stand alone as a drug-free option

Signos has received clearance from the U.S. Food and Drug Administration for what it says is the first over-the-counter glucose monitoring system designed for weight management, giving the Silicon Valley startup a regulatory edge in the booming metabolic health market.

The Palo Alto-based company packages an AI-powered platform with Dexcom’s Stelo continuous glucose sensor, allowing users to track how meals, activity, stress and even sleep affect their glucose levels in real-time. Signos says members report losing up to 7.75% of their starting weight within six months.

“This is more than a product launch — it’s a mission,” Signos founder and CEO Sharam Fouladgar-Mercer said. “Everyone deserves access to insights that help them live healthier, longer, more vibrant lives. Signos isn’t just about data; it’s about giving people ownership over their health and weight journeys in a way never before seen.”

The clearance follows a $20 million Series B funding round in 2023, led by Cheyenne Ventures and Google Ventures with support from Dexcom Ventures and Samsung Next. At the time, Signos said the capital would expand its team and fund additional metabolic health research.

Signos says its platform interprets glucose fluctuations and translates them into personalized, AI-driven recommendations that can guide everyday decisions on food, exercise and recovery. Signos offers two HSA/FSA-eligible subscription plans: a three-month option at $139 a month, which includes six CGM sensors and six adhesive patches shipped together, and a six-month plan at $129 a month, which includes 12 sensors and patches delivered in two shipments. Both provide two CGMs per month shipped quarterly.

“I’ve been using Signos for years now, and no matter my mental ups and downs, it is there to keep me in reality,” actress and Signos advisor Raven-Symoné said. “The reality is things change, levels change, but if you keep an eye on the overall picture, you can keep your health in the green. Signos gives me the confidence to enjoy life while being mindful of my body and what it needs.”

Signos also offers nutrition support through a partnership with Nourish, a telehealth platform that recently raised $70 million in a Series B round and connects users with registered dietitians. According to the company, 93% of members pay nothing out of pocket, while those who do incur costs receive a locked-in, lower price arranged by Signos, according to its website.

Even as new tools emerge in pharma and health tech, from GLP-1 weight loss drugs to digital monitoring platforms, nearly 74% of U.S. adults are overweight or obese, according to the Centers for Disease Control and Prevention and 88% are considered metabolically unhealthy. Global diabetes diagnoses are projected to reach 1.3 billion by 2050, most of them type 2 cases, the World Health Organization estimates.

The post Signos Scores FDA Clearance for First OTC Glucose Monitor for Weight Loss appeared first on Athletech News.